ArticleImmunity, inflammation and disease2025
Low Thoracic Muscle Mass: A Novel Indicator of Poor Prognosis in Patients With Severe Fever With Thrombocytopenia Syndrome.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Commentary on "Low Thoracic Muscle Mass: A Novel Indicator of Poor Prognosis in Patients With Severe Fever With Thrombocytopenia Syndrome".Immunity, inflammation and disease · 2026Article
- Low Thoracic Muscle Mass: A Novel Indicator of Poor Prognosis in Patients With Severe Fever With Thrombocytopenia Syndrome.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSevere fever with thrombocytopenia syndrome (SFTS) poses a serious threat to public health due to its high mortality. Low thoracic muscle mass predicts poor clinical outcomes in many diseases, but its significance in SFTS remains unclear.
methodsThis retrospective study involved 210 SFTS patients admitted to the First Affiliated Hospital of Anhui Medical University from 2020 to 2023. All subjects underwent chest computed tomography (CT) examination. Skeletal muscle index (SMI) was measured by CT images at the level of the twelfth thoracic vertebra (T12). The clinical data of patients from the survival and non-survival groups were compared, and the prognostic value of T12-SMI in SFTS patients was evaluated through least absolute shrinkage and selection operator regression and univariate and multivariate Cox regression.
resultsPatients in the non-survival group had a lower SMI. Receiver operating characteristic analysis indicated that SMI may predict adverse outcomes in patients with SFTS. Multivariate Cox regression analysis demonstrated that SMI was independently connected to negative outcomes of SFTS. T12-SMI was correlated with albumin and creatinine.
conclusionLow SMI is associated with adverse outcomes in patients with SFTS. SMI may serve as a reliable prognostic marker for SFTS in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.